{"nctId":"NCT00930176","briefTitle":"A Study Investigating Treatment Factor X in People With Factor X Deficiency","startDateStruct":{"date":"2010-01"},"conditions":["Factor X Deficiency"],"count":16,"armGroups":[{"label":"Human Coagulation FACTOR X","type":"EXPERIMENTAL","interventionNames":["Biological: Human Coagulation FACTOR X"]}],"interventions":[{"name":"Human Coagulation FACTOR X","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent given, or for subjects aged 12-17 years, have given written assent and whose parent/guardian has given written informed consent\n* At least 12 years of age at dtae of written informed consent\n* Have hereditary severe or moderate FX deficiency\n* Currently treated with Fresh Frozen Plasma FFP, Prothrombin Complex Concentrate PCC or factor IX/X concentrate\n* Must have a minimum of one spontaneous or menorrhagic bleed in the last 12 months which required treatment of FFP, PCC or factor IX/X concentrate. Newly diagnosed subjects who present at the hospital with a bleed may be included\n* Must have had at least 7 days, and ideally 10-14 days, since an infusion of either FFP, PCC or factor IX/X concentrate at Baseline Visit\n* Females of child bearing potential must have a negative result on a HCG based pregnancy test. If they are or become sexually active, they must practise contraception by using a method of proven reliability for the duration of the study\n\nExclusion Criteria:\n\n* Have a history of inhibitor development to FX or a positive result at the Screening Visit\n* Bleeding at the appointment for the PK assessment\n* Subjects who have thrombocytopenia\n* Have clinically significant liver disease\n* Known to have other coagulopathy or thrombophilia\n* Have known or suspected hypersensitivity to the investigational medicinal product or its excipients\n* Have abused chemicals or drugs within the past 12 months\n* Have a history of unreliability or non-cooperation\n* Participating or have taken part in another trial within the last 30 days, with the exception of BPL FX surgery study - Protocol Ten03. In such cases, subjects should have completed their End of Study Visit either before or on the day of Screening Visit for this study\n* Female subjects who are pregnant or lactating\n* Subjects planning greater than 4 weeks absence from the locality of the Investigational site, between the screening visit and the repeat PK assessment","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FX:C Incremental Recovery","description":"Incremental recovery is defined as the peak rise in plasma FX levels (IU/dL), as measured at 15, 30 and 60 minutes post-dose, divided by the dose (IU/kg).\n\nValue given is the mean of 31 results: 16 for Baseline Visit + 15 for Repeat PK assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":"21.01"}]}]}]},{"type":"PRIMARY","title":"FX:C Half-life","description":"Value given is the mean of 31 results: 16 for Baseline Visit + 15 for Repeat PK assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.36","spread":"22.89"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":16},"commonTop":["Headache","Nasopharyngitis","Back pain","Pain in extremity","Arthralgia"]}}}